Pegvaliase-Pqpz ( DrugBank: Pegvaliase, pegvaliase-pqpz )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 240 | フェニルケトン尿症 | 1 |
240. フェニルケトン尿症
臨床試験数 : 143 / 薬物数 : 90 - (DrugBank : 10) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 5
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05356377 (ClinicalTrials.gov) | May 25, 2022 | 27/4/2022 | Preliminary Study of Brain Effects of Palynziq-Related Changes in Phenylalanine in Individuals With PKU | A Preliminary Study of the Neurological and Neuropsychological Effects of Palynziq-Related Changes in Phenylalanine in Individuals With Phenylketonuria (PKU) | Phenylketonurias | Drug: Pegvaliase-Pqpz | University of Missouri-Columbia | BioMarin Pharmaceutical | Enrolling by invitation | 18 Years | 55 Years | All | 13 | United States |